menu
    • menu
    [{"orgOrder":0,"company":"Regent Pacific","sponsor":"Wanbang Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunits","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Regent Pacific","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Cutaneous spray","sponsorNew":"Regent Pacific \/ Wanbang Pharmaceutical Marketing and Distribution","highestDevelopmentStatusID":"12","companyTruncated":"Regent Pacific \/ Wanbang Pharmaceutical Marketing and Distribution"}]

    Find Clinical Drug Pipeline Developments & Deals by Regent Pacific

    Menu

    Regent Pacific

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Regent Pacific

                            Hong Kong arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Regent Pacific

                            Hong Kong arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lidocaine,Prilocaine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved

                            Sponsor : Wanbang Biopharmaceuticals

                            Deal Size : $4.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Regent Pacific's Strategic Partner Receives Approval from NMPA to Submit IND Application

                            Details : Under the License Agreement Regent Pacific is now entitled to receive a payment of approximately HK$6.24 million from Wanbang Pharmaceutical, which is payable within 30 business days. NMPA will now formally review Senstend™ for Clinical Trial Approval.

                            Brand Name : Senstend

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 02, 2020

                            Lead Product(s) : Lidocaine,Prilocaine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved

                            Sponsor : Wanbang Biopharmaceuticals

                            Deal Size : $4.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth